Ge Long Hui·2025-10-30 10:41Core Insights - Shanghai Pharmaceuticals reported a revenue of 215.072 billion RMB for the first nine months of 2025, representing a year-on-year growth of 2.60% [1] - The pharmaceutical manufacturing segment generated sales of 18.164 billion RMB, showing a decline of 0.66%, while the pharmaceutical distribution segment achieved sales of 196.908 billion RMB, with a growth of 2.91% [1] - The net profit attributable to shareholders for the same period was 5.147 billion RMB, a year-on-year increase of 26.96%, primarily due to a one-time special gain from changing the accounting treatment of a joint venture to a subsidiary [1] - Excluding one-time special gains, the adjusted net profit was 3.979 billion RMB, reflecting a decline of 1.85% year-on-year [1] - The company maintained a strong operating cash flow with a net inflow of 2.350 billion RMB, indicating high-quality development [1] - Shanghai Pharmaceuticals ranked among the top ten in the "2024 Annual Top 100 Pharmaceutical Industrial Enterprises by Main Business Revenue" and achieved an upgrade to AA rating in MSCI ESG ratings due to its strong ESG performance [1]